Application of TFEB (transcription factor-EB) as stroke marker and therapeutic target

A stroke and drug technology, applied in the field of biomarkers and therapeutic targets, can solve problems such as unclear effects

Active Publication Date: 2018-06-12
SHENYANG PHARMA UNIVERSITY
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, the role of TFEB in stroke is still unclear. Therefore, it is of great significance to clarif

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of TFEB (transcription factor-EB) as stroke marker and therapeutic target
  • Application of TFEB (transcription factor-EB) as stroke marker and therapeutic target
  • Application of TFEB (transcription factor-EB) as stroke marker and therapeutic target

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0060] Example 1: The expression of TFEB in the nucleus at different time points after permanent middle cerebral artery occlusion (pMCAO) in rats and the localization of TFEB in the nucleus at different time points after oxygen-glucose deprivation (OGD) in primary neurons

[0061] 1. Materials:

[0062] experimental animals

[0063] SD rats, male, weighing 260-280g, provided by the Animal Center of Shenyang Pharmaceutical University, animal certificate number: 211002300015664

[0064] cell

[0065] Rat primary cortical neurons: cortical neurons of neonatal rats (less than 24 hours after birth)

[0066] 2. Method:

[0067] 2-1. Establishment of permanent middle cerebral artery occlusion (pMCAO) model in rats

[0068] Preparation of pMCAO model according to Longa method

[0069] (1) Before the pMCAO operation, the rats were fasted for 12 hours, then anesthetized with 3.5% chloral hydrate (0.1mL / kg) intraperitoneally, fixed in a supine position, and cut an incision of abou...

Example Embodiment

[0134] Example 2 : Effect of specific overexpression or knockdown of TFEB on ALP function and ischemic injury after pMCAO

[0135] 1. Materials:

[0136] experimental animals

[0137] SD rats, male, weighing 260-280g, provided by the Animal Center of Shenyang Pharmaceutical University, animal certificate number: 211002300015664

[0138] 2. Method:

[0139] Experimental Design and Grouping

[0140] The first part: 3 hours to 48 hours after pMCAO, the change rule of TFEB and cell location SD male rats, weighing 260-280g, were randomly divided into sham operation group, model group (3, 6, 12, 24, 48 hours), 10 animals per group. The pMCAO model was established, and the cortical brain tissue of 5 animals was isolated at different time points for Western blot detection, and 5 animals were subjected to immunofluorescence detection at the same time to investigate the change rule and cell location of TFEB after pMCAO.

[0141] Part II: Effects of neuron-specific knockdown / overe...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of TFEB as a stroke marker and a therapeutic target. According to the application of the TFEB as the stroke marker and the therapeutic target, detecting the expression quantity of The TFEB can be applied to diagnosis of stoke, and overexpression of the TFEB can be applied to treating stroke, so that high significance to diagnosis and treatment of stroke can beachieved.

Description

technical field [0001] The invention relates to a biomarker and a therapeutic target, in particular to the application of TFEB as a stroke biomarker and a therapeutic target. Background technique [0002] Stroke is a neurological disease caused by various etiologies that cause lesions in the blood vessels supplying the brain. Worldwide, stroke is the leading cause of permanent disability and death in adults. It has become one of the three deadly diseases in the world. The main clinical treatment is thrombolysis, saving dying neurons in the ischemic area (penumbra) and promoting the recovery of nerve function after injury. Prevention and treatment of ischemic cerebrovascular disease is an urgent medical problem for human beings. At present, the US FDA has only approved tissue plasminogen activator (tPA) for thrombolytic therapy after stroke, but its treatment time window is very narrow, and it is only effective if it is used within 4.5 hours of stroke; there are also bleed...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12Q1/6883A61K45/00A61K38/17A61K38/49A61K31/4152A61P9/10
CPCA61K31/4152A61K38/1709A61K38/49A61K45/00C12Q1/6883C12Q2600/158C12Y304/21068A61K2300/00
Inventor 杨静玉吴春福刘月阳
Owner SHENYANG PHARMA UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap